These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 7510808)

  • 1. A cost analysis of approved antiretroviral strategies in persons with advanced human immunodeficiency virus disease and zidovudine intolerance.
    Bozzette SA; Parker R; Hay J
    J Acquir Immune Defic Syndr (1988); 1994 Apr; 7(4):355-62. PubMed ID: 7510808
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hematopoietic growth factors as adjuncts to antiretroviral therapy.
    Miles SA
    AIDS Res Hum Retroviruses; 1992 Jun; 8(6):1073-80. PubMed ID: 1380256
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Potential use of human stem cell factor as adjunctive therapy for human immunodeficiency virus-related cytopenias.
    Miles SA; Lee K; Hutlin L; Zsebo KM; Mitsuyasu RT
    Blood; 1991 Dec; 78(12):3200-8. PubMed ID: 1720698
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A comparison of zidovudine, didanosine, zalcitabine and no antiretroviral therapy in patients with advanced HIV disease.
    Torres RA; Barr MR; McIntyre KI; Thornton JR; Shay WM; Feldman RD; George NJ; Britton DJ
    Int J STD AIDS; 1995; 6(1):19-26. PubMed ID: 7727578
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hematologic toxicity of zidovudine in HIV-infected patients.
    Brogan KL; Zell SC
    Am Fam Physician; 1990 May; 41(5):1521-8. PubMed ID: 1692180
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety profile of didanosine among patients with advanced HIV disease who are intolerant to or deteriorate despite zidovudine therapy: results of the Canadian Open ddI Treatment Program.
    Montaner JS; Rachlis A; Beaulieu R; Gill J; Schlech W; Phillips P; Auclair C; Boulerice F; Schindzielorz A; Smaldone L
    J Acquir Immune Defic Syndr (1988); 1994 Sep; 7(9):924-30. PubMed ID: 7519674
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical uses of hematopoietic growth hormones in HIV-related illnesses.
    Mitsuyasu RT
    AIDS Clin Rev; 1993-1994; ():189-212. PubMed ID: 7692940
    [No Abstract]   [Full Text] [Related]  

  • 8. AIDS: Part II.
    Kessler HA; Bick JA; Pottage JC; Benson CA
    Dis Mon; 1992 Oct; 38(10):691-764. PubMed ID: 1396036
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Current perspectives on antiretroviral therapy.
    Fletcher CV
    Pharmacotherapy; 1993; 13(6):627-33. PubMed ID: 7508101
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Zidovudine, didanosine, or both as the initial treatment for symptomatic HIV-infected children. AIDS Clinical Trials Group (ACTG) Study 152 Team.
    Englund JA; Baker CJ; Raskino C; McKinney RE; Petrie B; Fowler MG; Pearson D; Gershon A; McSherry GD; Abrams EJ; Schliozberg J; Sullivan JL
    N Engl J Med; 1997 Jun; 336(24):1704-12. PubMed ID: 9182213
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Leukocytopenia due to zidovudine- and nevirapine-containing regimens in elderly patients with HIV infection.
    Yamamoto Y; Yasuoka A; Yasuoka C; Genka I; Teruya K; Kikuchi Y; Tachikawa N; Oka S
    Jpn J Infect Dis; 2000 Dec; 53(6):244-5. PubMed ID: 11227023
    [No Abstract]   [Full Text] [Related]  

  • 12. Cost effectiveness of low-dose zidovudine therapy for asymptomatic patients with human immunodeficiency virus (HIV) infection.
    Schulman KA; Lynn LA; Glick HA; Eisenberg JM
    Ann Intern Med; 1991 May; 114(9):798-802. PubMed ID: 1672806
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The use of hematopoietic growth factors in HIV infection and AIDS-related malignancies.
    Miles SA
    Cancer Invest; 1991; 9(2):229-38. PubMed ID: 1713806
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recombinant human erythropoietin in the treatment of anemia associated with human immunodeficiency virus (HIV) infection and zidovudine therapy. Overview of four clinical trials.
    Henry DH; Beall GN; Benson CA; Carey J; Cone LA; Eron LJ; Fiala M; Fischl MA; Gabin SJ; Gottlieb MS
    Ann Intern Med; 1992 Nov; 117(9):739-48. PubMed ID: 1416576
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment options in zidovudine intolerance or failure.
    Abrams DI
    AIDS; 1994 Sep; 8 Suppl 3():S3-7. PubMed ID: 7840914
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Modeling the use of triple combination therapy in five countries: nevirapine, Zidovudine, and Didanosine.
    Biddle AK; Simpson KN
    Value Health; 2000; 3(3):186-201. PubMed ID: 16464183
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A randomized trial (ISS 902) of didanosine versus zidovudine in previously untreated patients with mildly symptomatic human immunodeficiency virus infection.
    Floridia M; Vella S; Seeber AC; Tomino C; Fragola V; Weimer LE; Ricciardulli D; Milazzo F; Gritti FM; Mazzotta F; Ranieri S; Chiodo F; Moroni M; Cargnel A; Bassetti D; Giannini V; Cremoni L; Concia E; Sinicco A; Carosi G; Alberici F; Dianzani F
    J Infect Dis; 1997 Feb; 175(2):255-64. PubMed ID: 9203645
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of didanosine in the management of HIV-1 infection.
    Gazzard BG; Moyle GJ
    Antivir Ther; 1997 Jul; 2(3):135-47. PubMed ID: 11322269
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Zidovudine: a review of pharmacoeconomic and quality-of-life considerations for its use in patients with human immunodeficiency virus.
    Langtry HD; Palmer KJ; Benfield P
    Pharmacoeconomics; 1993 Apr; 3(4):309-37. PubMed ID: 10146993
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The use of hematopoietic hormones in HIV infection and AIDS-related malignancies.
    Miles SA; Golde DW; Mitsuyasu RT
    Hematol Oncol Clin North Am; 1991 Apr; 5(2):267-80. PubMed ID: 2022593
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.